Göttinger Graduiertenzentrum für Neurowissenschaften, Biophysik und Molekulare Biowissenschaften

Weber, Martin S., Prof. Dr.


  • 2003 Dr. med., Medical School of the University of Würzburg, Germany
  • 2002–2004 Residency in Neurology, Postdoctoral-fellowship, Institute of Clinical Neuroimmunology (Prof. Dr. R. Hohlfeld) and Department of Neurology (Prof. Dr. Th. Brandt) Ludwig-Maximilians University, Munich-Großhadern; Max-Planck-Institute for Neurobiology (Prof. Dr. H. Wekerle), Germany
  • 2004–2007 Postdoctoral-fellowship at the University of California, San Francisco, USA; Department of Neurology (Prof. Dr. S. Hauser), Laboratory of Prof. Dr. S. Zamvil
  • 2008–02/2011 Senior Scientist, Residency in Neurology, Department of Neurology (Prof. Dr. B. Hemmer), Technische Universität München, Munich, Germany
  • 03/2011 Reasearch group leader and board-certified Neurologist, since 10/2012
  • 09/2012 Habilitation (professorial qualification) and Venia legendi for Neurology, Department of Neurology, Technische Universität München, Munich, Germany
  • since 10/2012 ProFutura Research group leader at the Institute of Neuropathology (Prof. Dr. W. Brück), University Medical Center, Göttingen, Germany
  • since 04/2013 Senior physician (“Oberarzt”) at the Department of Neurology (Prof. Dr. M. Bähr), University of Göttingen, Germany, head of the neuroimmunology unit, University Medical Center, Göttingen, Germany
  • 07/2013-12/2017 appointed W2 Professor (tenure track) for „Translational Neuroinflammation“, University Medical Center, Göttingen, Germany
  • since 09/2016 Deputy head of the Laboratory for neurochemical analyses (including cerebrospinal fluid diagnostic), University Medical Center, Göttingen, Germany
  • since 04/2017 appointed Head of the interdisciplinary “Multiple Scerosis Center Göttingen”, University Medical Center, Göttingen, Germany
  • since 01/2018 Tenured W2 Professor for „Translational Neuroinflammation”, University Medical Center, Göttingen, Germany
  • since 10/2018 Managing Senior Physician “Geschäftsführender Oberarzt”, University Medical Center, Göttingen, Germany



Major Research Interests


    Dr. Weber’s research focuses on the role of antigen-presenting cells and B cells in Multiple Sclerosis and its experimental models. His primary interest is to elucidate the functional diversity of different phenotypes of B cells and antigen-presenting cells and to understand how these findings can be harnessed to accelerate therapeutic innovation in Multiple Sclerosis.




Homepage Department/Research Group
https://neuropathologie.umg.eu/forschung/arbeitsgruppen-labore/ag-martin-weber/


Selected Recent Publications


  • Häusler D., Häusser-Kinzel S., Feldmann L., Torke S., Lepennetier G., Bernard C.C.A., Zamvil S.S., Brück W., Lehmann-Horn K., Weber M.S., Functional characterization of reappearing B cells after anti-CD20 treatment of CNS autoimmune disease. Proc Natl Acad Sci U S A. 2018 Sep 25;115(39):9773-9778.

  • Romanelli E., Merkler D., Mezydlo A., Weil M.T., Weber M.S., Nikic I., Potz S., Meinl E. Matznick F., Kreutzfeldt M., Ghanem A., Conzelmann K.K., Metz I., Brück W., Routh M., Simons M., Bishop D., Misgeld T., Kerschensteiner M. Myelinosome formation represents an early stage of oligodendrocyte damage in multiple sclerosis and its animal model. Nat Commun. 2016 Nov 16;7:13275

  • Kinzel S., Lehmann-Horn K., Torke S., Häusler D., Feldmann L., Winkler A., Stadelmann C., Payne N., Saiz A., Reindl M., Bernard C.C., Lalive P.H., Brück W., Weber M.S., Myelin-reactive antibodies initiate T cell-mediated CNS autoimmune disease by opsonization of endogenous antigen. Acta Neuropathol. 2016 Jul;132(1):43-58

  • Molnarfi N., Schulze-Topphoff U., Weber M.S., Patarroyo J.C., Prod’homme T., Varrin-Doyer M., Shetty A., Linington C., Slavin A.J., Hidalgo J., Jenne D.E., Wekerle H., Sobel R.A., Bernard C.C.A., Shlomchik M.J., Zamvil S.S. MHC class II-dependent B cell APC function is required for induction of CNS autoimmunity independent of myelin-specific antibodies; J Exp Med., 2013 Dec 16;210(13):2921-37. 13

  • Hertzenberg D., Lehmann-Horn K., Husterer V., Cravens P.D., Kieseier B.C., Hemmer B., Brück W., Zamvil S.S., Stüve O., Weber M.S., Developmental maturation of innate immune cell function correlates with susceptibility to central nervous system autoimmunity; Eur J Immunol, 2013 Aug;43(8):2078-88.

  • Lehmann-Horn K., Schleich E. Hertzenberg D., Hapfelmeier A., Kümpfel T., von Bubnoff N., Hohlfeld R., Berthele A., Hemmer B., Weber M.S., Anti-CD20 B-cell depletion enhances monocyte reactivity in neuroimmunological disorders. J Neuroinflammation. 2011 Oct 26;8:146 5

  • Weber M.S., Prod´homme T., Patarroyo J.C., Karnezis T., Molnarfi N., Karnezis T., Lehmann-Horn K., Danilenko D.M., Eastham-Anderson J., Slavin A., Linington C., Bernard C.C.A., Martin F., and Zamvil S.S. B cell activation influences T cell polarization and outcome of anti-CD20 B cell depletion in CNS autoimmunity Ann Neurol. 2010 Sep;68(3):369-83.

  • Weber M.S., Prod´homme T., Youssef S., Rundle C.D., Dunn S.E.., Lee L. Patarroyo J.C., Stüve O., Sobel R.A., Steinman L. and Zamvil S.S. Type II monocytes modulate T cell-mediated autoimmunity Nat Med. 2007 Aug;13(8):935-43.

  • Dunn S.E., Youssef S., Goldstein M.J., Prod’homme T., Weber M.S., Zamvil S.S., and Steinman L. Isoprenoids determine Th1/Th2 fate in pathogenic T cells, providing a mechanism of modulation of autoimmunity by atorvastatin. J Exp Med. 2006 Feb;203(2):401-12. 13

  • Stüve* O., Youssef* S., Weber M.S., Nessler S., von Büdingen H.-C., Hemmer B., Steinman+ L. and Zamvil+ S.S.. Immunomodulatory synergy by combination of glatiramer acetate and atorvastatin in treatment of CNS autoimmunity (*Co-first authors, +Co-last authors). J Clin Invest 2006 Mar;116(4):1037-1044.

  • Weber M.S., Starck, M, Wagenpfeil S, Meinl E, Hohlfeld R, Farina C. Multiple sclerosis: glatiramer acetate inhibits monocyte reactivity in vitro and in vivo. Brain. 2004 Jun;127(Pt 6):1370-8.